In August, there was a lot of good news in the pharmaceutical and bio industry. Hanmi and Yuhan, leading domestic pharmaceutical companies, announced the news of the signing of a global technology transfer contract for the new drug pipeline, revealing the potential of R&D. The license agreements of domestic companies are developing.

Earlier this month, Hanmi transferred the global copyright of a new bio-drug to treat non-alcoholic steatohepatitis (NASH) to MSD in the US. The scale of technology transfer is about ₩1 trillion. The down payment without obligation to return is ₩10 million, and royalties based on sales after commercialization are separately received.

There is anoth